PRF Technologies FY2025 operating loss narrows 65.1% to $5.1 million; revenue falls to $17,000

Reuters03-27

PRF Technologies FY2025 operating loss narrows 65.1% to $5.1 million; revenue falls to $17,000

PRF Technologies published an annual report on Form 20-F for the fiscal year ended Dec. 31, 2025.
Revenue was USD 17,000, while net loss attributable to shareholders was USD 4.8 million.
Research and development expense fell 90.6% to USD 1.1 million, primarily due to extensive clinical trial costs in 2024, partly offset by additional R&D tied to LayerBio activities.
Cash and cash equivalents (including short-term deposits and restricted cash) were USD 4.1 million as of Dec. 31, 2025, and management said there is substantial doubt about the company’s ability to continue as a going concern.
Business updates included a March 2025 acquisition of the DeepSolar solar analytics technology and an August 2025 majority investment in LayerBio, with work progressing toward a Phase II clinical trial for OcuRing-K.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PRF Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001782), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622948891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622948891","market":"nz","top_or_hot":-1,"title":"PRF Technologies FY2025 operating loss narrows 65.1% to $5.1 million; revenue falls to $17,000","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PRF Technologies FY2025 operating loss narrows 65.1% to $5.1 million; revenue falls to $17,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          PRF Technologies published an annual report on Form 20-F for the fiscal year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue was USD 17,000, while net loss attributable to shareholders was USD 4.8 million.\n        </li>\n<li>\n          Research and development expense fell 90.6% to USD 1.1 million, primarily due to extensive clinical trial costs in 2024, partly offset by additional R&amp;D tied to LayerBio activities.\n        </li>\n<li>\n          Cash and cash equivalents (including short-term deposits and restricted cash) were USD 4.1 million as of Dec. 31, 2025, and management said there is substantial doubt about the company’s ability to continue as a going concern.\n        </li>\n<li>\n          Business updates included a March 2025 acquisition of the DeepSolar solar analytics technology and an August 2025 majority investment in LayerBio, with work progressing toward a Phase II clinical trial for OcuRing-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PRFX\">PRF Technologies Ltd.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001782), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PRF Technologies FY2025 operating loss narrows 65.1% to $5.1 million; revenue falls to $17,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPRF Technologies FY2025 operating loss narrows 65.1% to $5.1 million; revenue falls to $17,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PRF Technologies FY2025 operating loss narrows 65.1% to $5.1 million; revenue falls to $17,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          PRF Technologies published an annual report on Form 20-F for the fiscal year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue was USD 17,000, while net loss attributable to shareholders was USD 4.8 million.\n        </li>\n<li>\n          Research and development expense fell 90.6% to USD 1.1 million, primarily due to extensive clinical trial costs in 2024, partly offset by additional R&amp;D tied to LayerBio activities.\n        </li>\n<li>\n          Cash and cash equivalents (including short-term deposits and restricted cash) were USD 4.1 million as of Dec. 31, 2025, and management said there is substantial doubt about the company’s ability to continue as a going concern.\n        </li>\n<li>\n          Business updates included a March 2025 acquisition of the DeepSolar solar analytics technology and an August 2025 majority investment in LayerBio, with work progressing toward a Phase II clinical trial for OcuRing-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PRFX\">PRF Technologies Ltd.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001782), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3GLZHk:1","article_id":"2622948891","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622948891","pubTimestamp":1774559230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PRF Technologies published an annual report on Form 20-F for the fiscal year ended Dec. 31, 2025.Revenue was USD 17,000, while net loss attributable to shareholders was USD 4.8 million.Research and development expense fell 90.6% to USD 1.1 million, primarily due to extensive clinical trial costs in 2024, partly offset by additional R&D tied to LayerBio activities.Cash and cash equivalents  were USD 4.1 million as of Dec. 31, 2025, and management said there is substantial doubt about the company’s ability to continue as a going concern.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PRF Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syst","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PRFX":"PRF Technologies Ltd."},"translate_title":"PRF Technologies 2025财年运营亏损收窄65.1%至510万美元；收入降至17,000美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRFX":0.9},"content_text":"PRF Technologies FY2025 operating loss narrows 65.1% to $5.1 million; revenue falls to $17,000\n    \n\n\n          PRF Technologies published an annual report on Form 20-F for the fiscal year ended Dec. 31, 2025.\n        \n\n          Revenue was USD 17,000, while net loss attributable to shareholders was USD 4.8 million.\n        \n\n          Research and development expense fell 90.6% to USD 1.1 million, primarily due to extensive clinical trial costs in 2024, partly offset by additional R&D tied to LayerBio activities.\n        \n\n          Cash and cash equivalents (including short-term deposits and restricted cash) were USD 4.1 million as of Dec. 31, 2025, and management said there is substantial doubt about the company’s ability to continue as a going concern.\n        \n\n          Business updates included a March 2025 acquisition of the DeepSolar solar analytics technology and an August 2025 majority investment in LayerBio, with work progressing toward a Phase II clinical trial for OcuRing-K.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PRF Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-001782), on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622948891","isCrawlerRequest":true}